Coherus Oncology 将来の成長
Future 基準チェック /26
Coherus Oncologyは、35.8%と40.7%でそれぞれ年率35.8%で利益と収益が成長すると予測される一方、EPSはgrowで40.9%年率。
主要情報
35.8%
収益成長率
40.89%
EPS成長率
| Biotechs 収益成長 | 29.0% |
| 収益成長率 | 40.7% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 17 Aug 2026 |
今後の成長に関する最新情報
Recent updates
Seeking Alpha • Aug 19
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development
Summary Coherus Oncology retains a "Hold" rating as multiple pivotal data readouts approach for its lead oncology candidates in 2H 2026. The company's tagmokitug and casdozokitug programs offer multiple shots on goal, targeting large solid tumor markets, but further proof-of-concept is key to success. Initial phase 2 CADILYZE data for casdozokitug in 1st-line unresectable HCC is expected in Q4 2026, representing a major inflection point. The company faces near-term cash constraints, with funding sufficient for only 12 months and potential dilution risk if additional capital is required. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 07
CHRS: Anti Tumor Readouts And New Trial Collaboration Will Drive Future Upside
Analysts have trimmed their price target on Coherus Oncology to $10 from $12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. Analyst Commentary Bullish analysts covering Coherus Oncology continue to highlight reasons they see upside potential in the stock, even as formal price targets are reassessed.
ナラティブ更新 • Jul 02
CHRS: Anti Tumor Collaboration Will Shape Bullish Outlook
Coherus Oncology's analyst price target has shifted from $6.75 to $7.80, with analysts pointing to updated assumptions around revenue growth, profit margin expectations, and a lower future P/E multiple following recent research highlighting the company's anti tumor potential. What’s in the News for Coherus Oncology Coherus Oncology and Zumutor Biologics entered a clinical collaboration and supply agreement to run a Phase 1 trial of ZM008, an NK checkpoint anti LLT1 antibody, in combination with LOQTORZI (toripalimab tpzi) across several solid tumor types in the United States.
ナラティブ更新 • Jun 18
CHRS: Anti Tumor Potential And Accounting Shift Will Drive Future Upside
Analysts now frame Coherus Oncology around a revised price target of $4.00, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E, with Guggenheim's recent coverage citing the company's anti tumor potential as a key part of the rationale. What’s in the News for Coherus Oncology Coherus Oncology changed its independent registered public accounting firm on June 12, 2026, as the Audit Committee dismissed Ernst & Young LLP, effective the same day.ナラティブ更新 • Jun 03
CHRS: Anti Tumor Potential And Upcoming Readouts Will Shape Future Upside
Analysts have lifted their price target on Coherus Oncology to $4.00, citing stronger projected revenue growth, higher expected profit margins, and a lower future P/E multiple following recent Street research pointing to the company’s anti tumor potential. What's in the News No recent news items, periodical coverage, or key developments were provided for Coherus Oncology as of Wednesday, 3 Jun 2026.ナラティブ更新 • May 16
CHRS: Anti Tumor Readouts Will Shape Future Revenue Visibility And Profitability
Analysts have raised their fair value estimate for Coherus Oncology stock from $10.00 to $12.00, citing Guggenheim's recent initiation focused on the company's anti tumor potential as a key driver behind the updated price target and more optimistic assumptions around revenue growth, profit margins, and future P/E. Analyst Commentary Analysts pointing to the anti tumor opportunity see the recent fair value move to US$12.00 as a sign that expectations for the stock are improving, particularly in how the market might value future oncology revenue and profitability.ナラティブ更新 • Apr 29
CHRS: Lock Ups And Recent Equity Raise Will Shape Bullish Outlook
Analysts have adjusted their price target on Coherus Oncology to $6.75, reflecting updated views on discount rates, profit margin assumptions, and future P/E expectations, while keeping the fair value estimate unchanged at $6.75. What's in the News Lock up agreements on certain stock options of Coherus Oncology, Inc.ナラティブ更新 • Apr 15
CHRS: Upcoming Readouts And New Outperform Coverage Will Shape Oncology Upside
Analysts have lifted their price target on Coherus Oncology to $4.00, citing updated expectations for revenue growth, profit margins, and a slightly higher future P/E multiple informed by recent bullish research and new Outperform coverage ahead of key readouts. Analyst Commentary Recent research points to growing interest in Coherus Oncology as analysts respond to fresh coverage ahead of key clinical readouts.ナラティブ更新 • Apr 01
CHRS: Upcoming Readouts And Equity Raises Will Shape Oncology Outlook
Analysts have lifted their price target on Coherus Oncology to $6.75, highlighting higher assumed revenue growth of 64.35%, a stronger profit margin of 14.76% and a modestly lower future P/E of 55.41x, following fresh bullish coverage ahead of key readouts. Analyst Commentary Bullish Takeaways Bullish analysts see the new coverage and price target as a vote of confidence in Coherus Oncology's ability to convert its pipeline into revenue growth, reflected in the 64.35% revenue growth assumption built into current models.ナラティブ更新 • Mar 18
CHRS: Upcoming Readouts And Biomarker Data Will Support Stronger Oncology Outlook
Analysts have raised their price target on Coherus Oncology to $4.00, presenting the unchanged fair value in conjunction with a lower discount rate and significantly higher modeled revenue growth, while citing recent bullish initiation and Outperform ratings ahead of key readouts. Analyst Commentary Recent research coverage frames Coherus Oncology as a higher risk, higher reward idea, with enthusiasm around upcoming readouts balanced by concerns about execution and the durability of modeled revenue growth.ナラティブ更新 • Mar 03
CHRS: Upcoming Readouts And New Collaboration Will Shape Oncology Pipeline Outlook
Analysts have kept their average $6.75 price target on Coherus Oncology steady, as recent bullish coverage and Outperform initiations are balanced by updated assumptions that include a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts highlight that fresh Outperform initiations signal confidence that the current share price already reflects more cautious margin and P/E assumptions.ナラティブ更新 • Feb 17
CHRS: Upcoming Clinical Readouts Will Drive Reassessment Of Oncology Pipeline Potential
Analysts have raised their price target on Coherus Oncology from about $5.67 to $6.75, citing updated assumptions on revenue trends, margins, and future P/E following recent bullish coverage and the initiation of coverage on the name ahead of key clinical readouts. Analyst Commentary Bullish Takeaways Bullish analysts point to upcoming clinical readouts as a key potential catalyst that could help support the higher price target and justify updated P/E assumptions.ナラティブ更新 • Feb 03
CHRS: Upcoming Readouts Will Shape Revenue Visibility And Profitability Expectations
Analysts have raised their fair value estimate for Coherus Oncology from US$7.00 to US$10.00, citing a more constructive view on revenue trends, profitability and future P/E assumptions following recent bullish coverage ahead of key readouts. Analyst Commentary Recent research coverage has leaned positive, with bullish analysts pointing to a more constructive setup around upcoming clinical readouts and the valuation reset implied by the higher fair value estimate.ナラティブ更新 • Jan 20
CHRS: Future Biomarker And Index Inclusion Catalysts Will Support Stronger Oncology Outlook
Analysts have made a slight adjustment to their price target on Coherus Oncology to reflect updated assumptions around discount rate, revenue growth, and margins, while maintaining their fair value estimate at approximately $4.00 per share. What's in the News Coherus Oncology published preclinical and clinical biomarker research in Molecular Cancer Therapeutics on its anti CCR8 monoclonal antibody, now named tagmokitug, highlighting high selectivity, picomolar binding affinity and effector mediated killing of CCR8+ cells, with no off target binding reported (Molecular Cancer Therapeutics, December 2025).分析記事 • Jan 10
There's No Escaping Coherus Oncology, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 27% Share Price Rise
Coherus Oncology, Inc. ( NASDAQ:CHRS ) shareholders would be excited to see that the share price has had a great month...ナラティブ更新 • Jan 06
CHRS: Future Immune Activation And Biomarker Data Will Support Stronger Oncology Outlook
Analysts have maintained their price target for Coherus Oncology at US$4.00, citing updates to revenue decline assumptions, a slightly lower discount rate, a small improvement in projected profit margins, and a reduced future P/E multiple as the key drivers of the refreshed view. What's in the News Publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics on tagmokitug, an investigational anti-CCR8 monoclonal antibody with high selectivity and picomolar binding affinity targeting CCR8+ T regulatory cells in solid tumors (Molecular Cancer Therapeutics).ナラティブ更新 • Dec 13
CHRS: Future Immune Activation Data Will Support Stronger Oncology Outlook
Analysts have raised their price target for Coherus Oncology to approximately 4.00 dollars from about 1.10 dollars, citing a less severe expected revenue decline, a slight improvement in projected profit margins, and a marginally higher future earnings multiple, despite a modestly increased discount rate. What's in the News New multiomic tumor and blood biomarker data from the Phase 1b dose expansion arm of CHS-114 in recurrent or metastatic head and neck squamous cell carcinoma show significantly enhanced and sustained immune activation when combined with toripalimab (Key Developments).分析記事 • Nov 14
Revenues Working Against Coherus Oncology, Inc.'s (NASDAQ:CHRS) Share Price Following 26% Dive
The Coherus Oncology, Inc. ( NASDAQ:CHRS ) share price has softened a substantial 26% over the previous 30 days...ナラティブ更新 • Sep 11
Upcoming Clinical Data Will Reshape Immuno-Oncology Amid Uncertainties
Despite a decline in net profit margin, Coherus Oncology's significantly higher future P/E ratio reflects increased investor optimism, resulting in a raised consensus price target from $4.70 to $5.67. What's in the News Coherus Oncology received a deficiency notice from Nasdaq after its common stock closed below $1.00 per share for 30 consecutive business days, putting it at risk of delisting.分析記事 • Aug 10
Industry Analysts Just Upgraded Their Coherus Oncology, Inc. (NASDAQ:CHRS) Revenue Forecasts By 21%
NasdaqGM:CHRS 1 Year Share Price vs Fair Value Explore Coherus Oncology's Fair Values from the Community and select...分析記事 • Jul 24
Coherus Oncology, Inc.'s (NASDAQ:CHRS) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Those holding Coherus Oncology, Inc. ( NASDAQ:CHRS ) shares would be relieved that the share price has rebounded 35% in...分析記事 • May 18
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues
The Coherus BioSciences, Inc. ( NASDAQ:CHRS ) share price has fared very poorly over the last month, falling by a...分析記事 • May 15
Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates
Market forces rained on the parade of Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shareholders today, when the analysts...Seeking Alpha • Apr 17
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs
Summary Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hepatocellular carcinoma with a 17.2% complete response rate in phase 1 and is now in a phase 2 study. CHRS is still marketing Loqtorzi for nasopharyngeal carcinoma, with Q4'24 revenues of $7.5M representing 29% growth over the prior quarter. Read the full article on Seeking Alpha
新しいナラティブ • Apr 03
UDENYCA Divestiture And LOQTORZI Progress Will Forge Opportunity Amid Risks
UDENYCA divestiture and headcount reduction will strengthen the balance sheet and improve margins through reduced expenses.分析記事 • Mar 28
Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop
To the annoyance of some shareholders, Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shares are down a considerable 27% in...分析記事 • Mar 24
Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings
Strong earnings weren't enough to please Coherus BioSciences, Inc.'s ( NASDAQ:CHRS ) shareholders over the last week...分析記事 • Dec 21
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise
Despite an already strong run, Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shares have been powering on, with a gain of...Seeking Alpha • Dec 16
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Summary Coherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS holds $97.7 million in cash, $36.6 million in term loans, and $227.9 million in convertible notes, with $70.8 million in net revenues. CHRS is divesting their Udenyca franchise for $483.4 million, with potential milestone payments, following previous sales of Cimerli and Yusimry franchises. CHRS's financial and strategic moves indicate a cautious yet potentially rewarding horizon for investors. Read the full article on Seeking Alpha分析記事 • Nov 06
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%
To the annoyance of some shareholders, Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shares are down a considerable 30% in...分析記事 • Sep 22
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Unfortunately for some shareholders, the Coherus BioSciences, Inc. ( NASDAQ:CHRS ) share price has dived 27% in the...Seeking Alpha • Aug 13
Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Summary Coherus BioSciences, Inc. focuses on biosimilars and immuno-oncology treatments, with LOQTORZI and UDENYCA as key products. Coherus BioSciences' biosimilar IP shows potential for profitability, with strategic divestitures impacting its financial position post Q3 2024. UDENYCA drives most of CHRS's revenues, positioning it as its crown jewel with a 29% market share and strong payer coverage. The success of UDENYCA and the potential growth from LOQTORZI are critical to avoiding dilution risks and ensuring long-term financial stability. Despite some cash runway concerns, CHRS trades at a low valuation, so it leans towards a speculative “buy” for investors who understand the embedded biotech risks. Read the full article on Seeking Alpha分析記事 • Aug 07
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 0.5x Coherus BioSciences, Inc. ( NASDAQ:CHRS ) is...Seeking Alpha • May 31
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
Summary Coherus BioSciences, Inc. is relying on revenues from existing drugs and its developmental pipeline after selling off a major source of revenue in Cimerli. CHS-114, an anti-CCR8 antibody being developed by CHRS, is set to produce data at the ASCO 2024 Annual Meeting. Coherus BioSciences refers to Yusimry (a biosimilar Humira) as a non-core product, and could look to sell the drug, although revenues are growing. Read the full article on Seeking Alpha分析記事 • May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now
Key Insights Coherus BioSciences to hold its Annual General Meeting on 29th of May Total pay for CEO Denny Lanfear...Seeking Alpha • Mar 21
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Summary CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point to a strong Q1'24 for Udenyca, which could increase the market's confidence that CHRS can offset lost revenues from the Cimerli sale. CHRS has data in H1'24 from a phase 1 trial of its anti-CCR8 antibody, CHS-114, in solid tumors, adding a catalyst to the calendar. Read the full article on Seeking Alpha分析記事 • Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Unfortunately for some shareholders, the Coherus BioSciences, Inc. ( NASDAQ:CHRS ) share price has dived 29% in the...Seeking Alpha • Jan 17
Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Summary CHRS has a pipeline of biosimilars including Yusimry, Cimerli, and Udenyca. A new form of Udenyca, Udenyca Onbody, was approved in December 2023. CHRS also has a new drug Loqtorzi (toripalimab) which was approved in the US for the treatment of nasopharyngeal carcinoma in October 2023. Approval of Loqtorzi is a key step towards creating a revenue source with a greater moat versus biosimilars. Read the full article on Seeking Alpha分析記事 • Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.1x Coherus BioSciences, Inc. ( NASDAQ:CHRS ) is...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 168 | -99 | 5 | N/A | 6 |
| 12/31/2027 | 100 | -133 | 5 | N/A | 6 |
| 12/31/2026 | 61 | -139 | -81 | -90 | 6 |
| 6/30/2026 | 51 | -161 | -186 | -186 | N/A |
| 3/31/2026 | 47 | -173 | -171 | -171 | N/A |
| 12/31/2025 | 42 | -183 | -151 | -139 | N/A |
| 9/30/2025 | 278 | 61 | -103 | -90 | N/A |
| 6/30/2025 | 32 | -185 | -118 | -106 | N/A |
| 3/31/2025 | 32 | -195 | -24 | 1 | N/A |
| 12/31/2024 | 26 | -215 | -33 | -20 | N/A |
| 9/30/2024 | 110 | -249 | -74 | -62 | N/A |
| 6/30/2024 | 179 | -242 | -67 | -54 | N/A |
| 3/31/2024 | 227 | -230 | -153 | -153 | N/A |
| 12/31/2023 | 257 | -238 | -175 | -175 | N/A |
| 9/30/2023 | 211 | -217 | -229 | -262 | N/A |
| 6/30/2023 | 182 | -264 | -213 | -245 | N/A |
| 3/31/2023 | 183 | -271 | -225 | -256 | N/A |
| 12/31/2022 | 211 | -292 | -276 | -241 | N/A |
| 9/30/2022 | 239 | -279 | -231 | -193 | N/A |
| 6/30/2022 | 276 | -230 | -180 | -143 | N/A |
| 3/31/2022 | 304 | -210 | -121 | -93 | N/A |
| 12/31/2021 | 327 | -287 | -39 | -37 | N/A |
| 9/30/2021 | 364 | -232 | -90 | 48 | N/A |
| 6/30/2021 | 395 | -165 | -60 | 82 | N/A |
| 3/31/2021 | 443 | -76 | -16 | 142 | N/A |
| 12/31/2020 | 476 | 132 | 139 | 154 | N/A |
| 9/30/2020 | 489 | 162 | 113 | 139 | N/A |
| 6/30/2020 | 487 | 181 | 125 | 146 | N/A |
| 3/31/2020 | 435 | 145 | N/A | 99 | N/A |
| 12/31/2019 | 356 | 90 | N/A | 28 | N/A |
| 9/30/2019 | 232 | -12 | N/A | -37 | N/A |
| 6/30/2019 | 121 | -118 | N/A | -134 | N/A |
| 3/31/2019 | 37 | -185 | N/A | -183 | N/A |
| 12/31/2018 | N/A | -209 | N/A | -159 | N/A |
| 9/30/2018 | N/A | -196 | N/A | -142 | N/A |
| 6/30/2018 | N/A | -196 | N/A | -141 | N/A |
| 3/31/2018 | 1 | -208 | N/A | -161 | N/A |
| 12/31/2017 | 2 | -238 | N/A | -200 | N/A |
| 9/30/2017 | 2 | -265 | N/A | -257 | N/A |
| 6/30/2017 | 165 | -122 | N/A | -278 | N/A |
| 3/31/2017 | 178 | -137 | N/A | -250 | N/A |
| 12/31/2016 | 190 | -127 | N/A | -253 | N/A |
| 9/30/2016 | 199 | -104 | N/A | -160 | N/A |
| 6/30/2016 | 44 | -259 | N/A | -158 | N/A |
| 3/31/2016 | 37 | -248 | N/A | -151 | N/A |
| 12/31/2015 | 30 | -223 | N/A | -108 | N/A |
| 9/30/2015 | 26 | -200 | N/A | -147 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: CHRS今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: CHRS今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: CHRS今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: CHRSの収益 ( 40.7% ) US市場 ( 13.4% ) よりも速いペースで成長すると予測されています。
高い収益成長: CHRSの収益 ( 40.7% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: CHRSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/14 08:22 |
| 終値 | 2026/09/11 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Coherus Oncology, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Colleen Kusy | Baird |
| Balaji Prasad | Barclays |
| Mayur Somaiya | BMO Capital Markets Equity Research |